netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Introduction

Preferred Prescribing list for North Staffordshire CCGs, including University Hospitals of North Midlands NHS Trust, Midlands Partnership NHS Foundation Trust and North Staffordshire Combined Healthcare NHS Trust

Useful Links

ESCAs Guidelines and Clinical Pathways Patient Group Directions
Formulary Documentation High Cost Drugs Information Drug Discontinuations & Shortages
Area Prescribing Committee Documents New Medicines Committee Documents Monthly Newsletters
Self Care and Over the Counter Medicines Prescribing Decline To Prescribe Form  Care Home Prescribing Resourses

 CCG Formularies

South Staffordshire Joint Formulary  Central & Eastern Cheshire Formulary  Birmingham & Surrounds Formulary

Clinical Formularies

Woundcare Formulary Continence Prescribing Formulary Antimicrobial Guidelines
How to guide for North Staffordshire Joint Formulary  

 

News Feed

19/03/20 Esmya: Urgent patient level recall

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Ulipristal acetate (Esmya) from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Clinicians must contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should be provided advice about other possible treatments for uterine fibroids.  


24/02/20: Three Insuman preparations to be discontinued.

Three presentations of Insuman Basal and Insuman Comb are to be discontinued owing to limited capacity at the manufacturing site. The manufacturer says the discontinuations are not due to any safety issue.

The presentations being discontinued are:

  • Insuman Comb 15 100IU/mL suspension for injection in a cartridge (expected end of supply June 2020). This is the only presentation of Insuman Comb 15.
  • Insuman Basal 100IU/mL suspension for injection in a vial (expected end of supply May 2020).
  • Insuman Comb 25 100IU/mL suspension for injection in a vial (expected end of supply June 2020).

No new patients should be started on these presentations, and existing patients should be switched to a suitable alternative. See individual entries on the formulary for alternatives.

 


24/12/19: Antimicrobial guidelines for Staffordshire and Stoke CCGs

The Staffordshire and SOT Antimicrobial prescribing guidelines for managing common infections in primary care have been updated. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team.


21/11/19: Asthma guidelines for Staffordshire and SOT CCGs

The APC/APG has approved the Staffordshire and SOT CCGs Asthma Guidelines. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team. 


14/11/19: Updated Renal ESCAs in North Staffs (approved by APC)

Clinicians should take note of the updated ESCAs for Lanthanum and Sevelamer, both used for the treatment of hyperphosphatemia in pre-dialysis CKD patients in North Staffordshire. Any questions relating to these documents can be sent to the Medicines Optimisation team.


14/10/19: Update on current supply issue of all brands of adrenaline auto-injectors

Clinicians should note the latest stock availability update from DHSC concerning adrenaline auto-injectors (see table below). Due to the supply issues with some brands, it may be necessary to switch patients to an alternative brand that they are unfamiliar with. Clinicians should support switching and ensure patients know how to use the alternative product that is supplied. 

Adrenaline auto-injector brand
Strength
MA Holder
Stock Availability
EpiPen Junior
150 micrograms
Mylan UK
Available under prescription validation
EpiPen
300 micrograms
Mylan UK
Available under prescription validation
Jext
150 micrograms
ALK-Abello
Available
Jext
300 micrograms
ALK-Abello
Available from w/c 14th October
Emerade
150 micrograms
Bausch & Lomb
Available
Emerade
300 micrograms
Bausch & Lomb
Available from w/c 14th October
Emerade
500 micrograms
Bausch & Lomb
Available from 18th October

Specific training and advice are required for each of the devices. Please follow the links to the relevant training videos below:

EpiPen:            http://www.epipen.co.uk/demonstrationvideo/

Jext:                 https://hcp.jext.co.uk/

Emerade:          https://www.emerade-bausch.co.uk/patient/how-to-use-emerade


>>> more news

 

 


NetFormulary
   Visits = 30563
   Last updated: 07/04/2020 07:53:13..